CambridgeIP
CambridgeIP: News and Updates 

April 2010
In This Issue
Harvard Business Review Features CambridgeIP
Inhaler Drug Delivery Innovation
CambridgeIP & Chatham House CleanTech Report
Economics of Climate Change
Patents and Stem Cell Research
CambridgeIP Events
CambridgeIP Team News
CambridgeIP Publication & Media

CIP Univ Logo gif
CambridgeIP is a leading provider of technology business intelligence and IP-based strategy services to the technology community, capital firms, and policy makers. 
 
Contact us today for more information on how we can provide fact-based input for your key technology and IP strategy decisions.
 
Contact Ilian Iliev
CEO & co-Founder
Contact Quentin Tannock, Chairman & co-Founder
Contact Mark Meyer
N. American Buisness Development Manager
 
Contacts: 
UK +44-1223-370-098
US +1-281-377-4260
 
CambridgeIP is headquarted in Cambridge, UK with representation in Boston, Houston, London and Geneva.

Quick Links
Greetings!

We would like to take a moment and share some of our exciting news and updates with you. Below you can learn more about:

- A recent Harvard Business Review article citing CambridgeIP's joint research with Chatham House in the CleanTech space

- Emerging trends in the inhaler drug delivery space 

- Important developments in stem cells patenting
 
- Our new team members, Dr Robert Brady and Mr Peter Harverson

-The latest CambridgeIP Publications and Events information.

...and much more.
HBR_Logo
Harvard Business Review Article Features CambridgeIP Research

Harvard Business Review featured CambridgeIP research on cleantech in its January/February edition ('Can Technology Really Save Us from Climate Change?' Harvard Business Review). HBR's authors believe the CambridgeIP patent landscaping framework can underpin a 'Moore's Law' for low-carbon energy technologies. A 'Moore's Law'  can  support  government and business decision making around long-term low-carbon energy deployment. 
"To cut global emissions in half over the next 40 years, as scientists recommend, clean technologies must be rolled out on a vast scale. In the past, they have taken 19 to 30 years to achieve wide use, say researchers at the UK think tank Chatham House and the patent-search firm CambridgeIP... To be sure, powerful new market forces are at work: Governments beyond Europe are set to impose limits on greenhouse gases, and companies in a range of sectors are searching hard for ways to curb emissions. But technology deployment always takes time...That is particularly true of energy-related inventions, which tend to get into big trouble on their way out of the incubator and into the marketplace" (Harvard Business Review, January/February 2010:p. 21)

"The ability for IP Landscapes to track and analyze the clean-tech direction could 'pave the way for more-focused innovation, more-efficient use of capital, and more-realistic regulations".

For the full HBR article click here. See below for more on the Chatham House - CambridgeIP report 'Who owns our low-carbon future?'
 
Powder Inhaler (Patent #US7252087)
DPI Inhaler
Inhaler Drug Delivery Innovation: A New Era for the Pharmaceutical Propellants?

CambridgeIP's Arthur Lallement presented at the Drug Delivery for Lungs conference at Edinburgh on December 9, 2009. Over four hundred senior scientists from the inhaler and respiratory disease industry attended the conference and shared some of the latest research in the inhaler space.
 
For the last 20 years, the pharmaceutical industry has been developing propelled formulations based on HydroFluoroAlcanes (HFA) in order to comply with the Montreal Protocol banning the use of the ChloroFluoroAlcanes depleting the ozone layer. Many of the inhaler industry's key players were impacted significantly by the CFC ban, and in particular those in the Propelled Metered Dose Inhaler (pMDI) space. Industry players' strategy to adapt to the Montreal Protocol has broadly followed two directions: pMDI space innovation and moving out of PMDIs.
 
Now almost 20 years later, many of the original propellant HFA patents are expiring. This will result in many opportunities as well as threats for key industry players. The patent expiration's will allow the pharmaceutical industry to develop new pMDI formulations and to market generic pMDI formulations...
 
...To continue reading about the 'New Era for the Pharmaceutical Propellants' see our blog article here, including a presentation on HFA pMDI Patent Landscape.

Additionally, CambridgeIP is holding a free Webinar on the topic of 'Inhaler Devices: Evolution, Regulatory Impact and Emerging Innovations - Evidence and Techniques from patent-based analysis' on Tuesday 27 April 2010; 15.00 - 16.00 UK time.
To register please contact Sarah.Helm@cambridgeip.com.
 
If you would like to learn more about CambridgeIP's drug delivery device offering, please contact ilian.iliev@cambridgeip.com
 
Chatham/CambridgeIP Report
'Who Owns Our Low-carbon Future?' CambridgeIP and Chatham House Report on Clean-Tech

Research conducted by CambridgeIP jointly with Chatham House (the Royal Institute of International Affairs) has uncovered interesting trends that can inform investment and growth strategies for companies in the low-carbon energy space.

CambridgeIP undertook an extensive analysis of patent ownership and the market adoption rates of six low-carbon energy technologies: wind, solar photovoltaic (PV), concentrated solar power, biomass-to electricity, clean coal and carbon capture. We also looked at how company strategies relate to different industry IP practices (such as cross-licensing agreements or technology standards).

Research and analysis revealed that the pace of deployment in the six clean-tech sectors is picking up.  And this increasing deployment potentially suggests that the time to market could be predictable for some clean technologies by comparing patenting activity and technology roll-out. In addition, growing complexity of the patent landscape in Wind and PV may be contributing to increased IP litigation in these spaces.

For access to the full report from CambridgeIP and Chatham House click here.
 
To find out more about CambridgeIP's CleanTech practice, please contact Ilian Iliev in the UK (ilian.iliev@cambridgeip.com) or Mark Meyer in North America (mark.meyer@cambridgeip.com)
 
Quentin Tannock presents a Chevening Lecture at Cambridge University on 'The Economics of Climate Change' 

Following the Stern Review on 'the Economics of Climate Change', the Foreign and Commonwealth Office established a Chevening Fellowship course focusing on this topic. Each year the Course brings together a group of Fellows who have responsibility for advising their governments around the world on climate change. 

Quentin Tannock (Chairman and Founder) of CambridgeIP was invited by the University of Cambridge Programme for Sustainable Leadership, who are currently hosting the lectures, to present on research CambridgeIP has published. Quentin presented on the topic of 'The Economics of Climate Change: IP Ownership, Taking the Lead', covering ethical and policy issues, the facts on the ground in terms of IP ownership, the impact of international conventions and national policies on IP activity and the range of options for technology transfer in Low Carbon Technology spaces.

Quentin concluded that much applicable Low Carbon Technology already exists, and the drivers and mechanisms for technology owners to undertake technology deployment can be identified. Policy-makers need to develop 'smart' technology and IP policies that consider the diversity of technologies, markets and players. Significant challenges remain with respect to valuation of, payment for and deployment of existing applicable technologies. However, much can be done to improve the transparency and efficiency of the current IP system, without radical overhaul. Importantly, patents published around the world represent a global technology library containing a wealth of freely available information. Improving access to this wealth of science and technology data should be a priority for policy-makers.

To view the summary lecture presentation and entire blog piece on 'The Economics of Climate Change: IP Ownership, Taking the Lead' click here.
'Patents and Potency' Julian Hitchcock guest authors a piece on patenting in the complex world of stem cells

[An excerpt from the article]

The grant of a patent for induced pluripotent stem cells (iPSCs) in the United Kingdom in January and the notice issued by the US Patent and Trademark Office in February allowing claims under a US patent application entitled "Methods for Reprogramming Somatic Cells" signal a significant new feature of the stem cell patent landscape. But don't imagine that stem cell patents are about to become straightforward.-

Paradigm Shift

The law can sometimes be illuminated by a ludicrous interpretation. Such is the case as regards the prohibition on patenting "processes for modifying the germ line genetic identity of human beings" (Article 6b / Rule 28b): the fact that a blot of induced totipotent cells never goes on to take out a mortgage and raise a family being as irrelevant as the purpose that happens to be stated in the relevant patent application. The exception is questionable on many grounds. Ethically, it stands opposed to the natural wish of parents to ensure that their children are unharmed by genes which they would otherwise inherit. Technically, it takes no account of the role of epigenetics: for example, it would prevent the patentability of factors which might be applied in utero to counter diseases arising from genomic imprinting. Indeed, epigenetics,- the control of genetic expression by factors outside the genome, is ultimately what iPSC technology is all about. One can put it more strongly still, by saying that it is putting the cart before the horse to talk of cells before talking of those factors which determine their fate: cells are all phenotype, while th eir fate is determined by genomic control.
Julian_Hitchcock

- The author, Julian Hitchcock, is a Senior Associate of Field Fisher Waterhouse LLP and Executive Director of the East of England Stem Cell Network.

To read the full article click here.
To learn more about CambridgeIP's work in stem cells contact quentin.tannock@cambridgeip.com
 
CambridgeIP Upcoming Events

This Week:

CambridgeIP will run an online webinar on the 27th of April for a small group on the topic of Inhaler Devices: Evolution, Regulatory Impact and Emerging Innovations - Evidence and Techniques from patent-based analysis

Synopsis: Ilian Iliev (CEO) and Arthur Lallement (Senior Associate) will present CambridgeIP research on the evolution of inhaler innovation in the DPI and pMDI spaces.  The speakers will discuss two case study examples of how innovation is impacted by regulatory changes in the DPI and pMDI spaces - around HFA propellants and dose counters.   The session will cover emerging trends and developments, and examples of emerging technologies in the inhaler space will be provided.

27 April 2010, Start time 15.00 UK Time  - End time 16.00 UK Time.
Attendance is free

To register and obtain joining instructions contact Sarah Helm (Sarah.Helm@cambridgeip.com)

Mark your calenders:

6th May 2010:
Quentin Tannock (Chairman) will present at BIO 2010 in Chicago, USA on the topic of "Fact-based strategy development: Accelerating your out-licensing". Case study examples will be provided from the Inhalers sector and Quentin will discuss Inhaler Related Evolution, Regulatory Impact and Emerging Innovations.

11th May 2010:
CambridgeIP is running a free online webinar lead by Mark Meyer (N. American Business Development Manager) for a small group on the topic of US Practices.

13th-14th May 2010: Ilian Iliev (CEO) was invited to speak at the 'Trade, Financing and Climate Change: Towards a positive agenda for developing countries' conference hosted by Chatham House and DFID on the topic of: Intellectual Property and Low Carbon Technological Diffusion

18th May 2010: CambridgeIP is running a free online webinar lead by Quentin Tannock (Chairman) for a small group on the topic of Developing a Fact Based IP Strategy.

1st June 2010: CambridgeIP is running a free online webinar lead by Quentin Tannock (Chairman) for a small group on the topic of Nanotechnology.

15th June 2010: CambridgeIP is running a free online webinar lead by Helena van der Merwe (Senior Associate) on the topic of Telecoms.

Details of the upcoming webinars are still being organized, but if any of the topics are of interest please contact Sarah.Helm@cambridgeip.comfor further information closer to the date.

CambridgeIP Team News

We are pleased to announce two new additions to the CambridgeIP team. Dr Robert Brady has joined our Board of Directors, and Mr Peter Harverson has joined our Advisory Board.  See profiles of both of our latest team members below.

Dr Robert Brady has joined the CambridgeIP Board as a non-Executive Director. Dr Brady acts as an active mentor and advisor for several growth companies, specializing in information technology and services.  He is current treasurer of Cambridge Angels investment group.  Previously, Dr Brady was a Fellow at Trinity College, Cambridge where he specialized in the field of physics. His published research includes two articles in Nature on computer optimization strategies and electrolysis of copper sulfate.  In 1985 he began his commercial career with the founding of Brady plc.  Brady plc has grown into a leading supplier of transaction and risk management software solutions to companies and banks operating in the metals and minerals, energy and 'soft' commodity sectors.



Mr Peter Harverson has joined the CambridgeIP Advisory Board.  Mr Harverson has held a number of senior executive roles at NASDAQ
DPI Inhaler
/NYSE companies such as Texas Instruments, Intel Corp, Daisy Systems, Valid Logic, Cadence Design Systems and Sun Microsystems. Notably, while at Sun Microsystems he headed the entire development of the companies European Corporate Accounts programme. More recently Peter Haverson has used his technical background and extensive experience of on technology market to assist in the operational management of numerous growth companies. Mr Peter Haverson currently acts as non-executive director to Ubisense Ltd, Aspex Semiconductor Holdings Ltd, CRFS Ltd and as an adviser to Pulsic Ltd.

Other News

Ilian Iliev
(CEO & Founder) was recently appointed as an Associate Fellow at Chatham House.
Read More: CambridgeIP Publications, Presentations and Media

Links to the most recent CambridgeIP Publications and Media. For a complete archive see here.

Publications & Media

'Can Technology Really Save Us from Climate Change?' Harvard Business Review [January/February 2010 edition].

'Challenges and Opportunities in the licensing of renewable technologies' Journal of Commercial Biotechnology[Volume 16, Issue 1; pp. 47-52]. Article co-authored by Meredith Lloyd-Evans, Mike Gilbert, and Ilian Iliev.

'The Importance of IP' Renewable Energy Focus Finance Supplement (pp. 18-20). Ilian Iliev and Mark Meyer.

'Heavy industry key to carbon reduction',interview with Ilian Iliev, The Engineer, September 2009.

Presentations

Quentin Tannock of CambridgeIP presented a Chevening Fellowship Lecture at the University of Cambridge on 'The Economics of Climate Change: Taking a lead - IP Ownership'.

Ilian Iliev of CambridgeIP presented at the CUTEC 'Leveraging IP in a Globalised World'workshop in Cambridge addressing the development of intellectual property in a globalised economy.

CambridgeIP presented with Dr. Phillippe Rogueda at the Drug Delivery to the Lungs (DDL) conferenceon the topic of 'The HFA pMDI Patent Landscape: Minefield or Goldmine?'.

Mark Meyer of Cambridge IP presented at the American Institute of Chemical Engineers (AICHE) Spring Meeting in San Antonio. The topic presented was regarding 'IP Strategy Options for Emerging Technologies in the Low-Carbon Energy Space'.

Social Media

CambridgeIP is now on Twitter! Follow us to keep up with the latest news and updates.

To stay connected with CambridgeIP's professional network, join our LinkedIn group.
About CambridgeIP

Please feel free to get in touch with our principals:
Quentin Tannock: quentin.tannock@cambridgeip.com
Ilian Iliev: ilian.iliev@cambridgeip.com
Mark Meyer: mark.meyer@cambridgeip.com

Tel UK +44-1223-370-098
Tel US +1-281-377-4260

About Us

CambridgeIP is a provider of technology, business intelligence and IP strategy services to the technology community and policy makers.

The company has a proprietary platform enabling efficient handling, real time analysis and online display of large patent (and other structured data) datasets, unique analytics, and highly granular focus at the level of individual technology, inventor or organisation. We provide fact-based IP strategy, R&D and investment due diligence services to the technology community at large. 

We have representatives in Cambridge and London (UK), Houston and Boston (USA) and Geneva (Switzerland)

Mailing Address:
Cambridge Intellectual Property Ltd,
Sheraton House, Castle Park, Cambridge, CB3 0AX, United Kingdom
Visit www.cambridgeip.com for more details.

Disclaimer

This newsletter includes analysis, together with opinions or financial observations expressed by CambridgeIP. They do not constitute legal advice. The reader should not rely on them to make (or to refrain from making) any decision. Any decision is the reader's sole responsibility.